RxDoctor Payments Data

Quang Tran

Family · Long Beach, CANPI 1497269864

Payments from drug & device makers

$3,691in general payments, 2019–2025

Across 158 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$806
  • GSK$555
  • AstraZeneca$416
  • Novo Nordisk$372
  • Amgen$339
  • Gilead$306
  • plus $896 from 14 others

What the payments were for

  • Food & beverage$3,684100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,691 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol643$349,358
RybelsusSemaglutide189$170,967
KerendiaFinerenone185$116,885
VemlidyTenofovir Alafenamide64$86,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter111$68,020
VascepaIcosapent Ethyl214$61,364
JardianceEmpagliflozin88$51,871
DapagliflozinDapagliflozin Propanediol95$45,397
Diclofenac Sodium124$34,431
OzempicSemaglutide26$30,569
Icosapent Ethyl225$27,154
TrulicityDulaglutide22$27,024
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$23,591
EliquisApixaban39$19,167
Albuterol Sulfate HfaAlbuterol Sulfate450$16,068

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$416$372,949682 claims
Novo NordiskRybelsus, Ozempic$372$201,536215 claims
BayerKerendia$806$116,885185 claims
GileadVemlidy$306$86,44264 claims
GSKTrelegy Ellipta, Breo Ellipta$555$79,330138 claims
Boehringer IngelheimJardiance$93$51,87188 claims
Lilly USA, LLCTrulicity$165$27,02422 claims
PfizerEliquis$27$19,16739 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →